However, positive results were only demonstrated in CEA, CA125, NSE, and CYFRA21-1 in NSCLC patients with relatively lower positive rates of 22.50%, 5.88%, 5.88%, and 37.93%, respectively (Table S1), suggesting that the traditional routine biomarkers are not sensitive enough to distinguish NSCLC patients from healthy individuals. The gene discussed is ENO2; the disease is non-small cell lung carcinoma.